2C — September 15 - 28, 2017 — Pennsylvania — M id A tlantic

Real Estate Journal


P ennsylvania

hiladelphia has again burst onto the interna- tional scene with the re- Biopharma is clustering around Greater Philadelphia’s R&D expertise Welcome to “Cellicon Valley” - Philadelphia P

We know Real Estate

Our dedicated real estate attorneys provide comprehensive legal

• Negotiation • Due diligence • Permits & Approvals • Title insurance • Entity formation • Settlement • Tax assessment appeals

ple scientists recently reached a pinnacle moment when they demonstrated that HIV can be removed from infected cells in animals. Through gene editing technology, the Temple team removed the virus from animal cells, and are the first research- ers to replicate the process in three different animal models – including in a “humanized” model. In addition, Philadelphia’s Spark Therapeutics is lead- ing the way in genetic disease research by discovering and developing therapies for inher- ited retinal diseases (IRDs) and neurodegenerative diseases, among others. One of Spark’s medicines in development has received breakthrough therapy and orphan product designa- tions from the FDA, as well as orphan product designation from the European Medicines Agency. FDA Commissioner Scott Gottlieb commented in a news release that we are “entering a new frontier in medical in- novation with the ability to reprogram a patient’s own cells to attack a deadly cancer.” That new frontier is being shaped in Philadelphia.

Based on Philadelphia’s deep and remarkable history as an epicenter of medical research, it is no wonder these medi- cal milestones are happening here. With 7 medical schools, 3 schools of pharmacy, 2 dental schools, a school of podiatric medicine, a school of optometry, and a renowned school of vet- erinary medicine, the region is leading the way in innovative, collaborative research that are delivering medical break- throughs. Add to these remark- able ingredients the fact that Greater Philadelphia is home to nearly 500 medical institu- tions - including 5 children’s hospitals and 4 National Can- cer Institute-designated cancer research centers – and the question for biotech and phar- maceutical leaders around the world is not if they should have operations in our 11-county community, but can they afford to not call Greater Philadelphia home. Matt Cabrey leads Select Greater Philadelphia, a business attractionmarket- ing organization for north- ern Delaware, southern New Jersey, and southeast- ern Pennsylvania. n

services to assist clients in every stage of the real estate transaction. We regularly represent developers, businesses, public entities and individuals.

cent U.S. reg- ulatory ap- proval of the world’s first gene t i ca l l y eng i nee r ed immune ther- apy, a T-cell t r e a t m e n t for pediatric

ListedbyU.S.News - Best Lawyers® asa 2017 HarrisburgTier1 “Best LawFirm” in six practice areas, andTier 2 firm in one practice area.

www.barley.com @barleysnyder


Matt Cabrey

leukemia developed at the University of Pennsylvania in collaboration with Children’s Hospital of Philadelphia and Novartis. It’s fitting that the U.S. Food and Drug Adminis- tration (FDA) referred to their endorsement of this new gene therapy as a “historic action,” considering that Philadelphia is home to major milestones in medical research and life sciences. Combine the Penn-developed T-cell treatment for pediat- ric leukemia with the break- through gene editing technol- ogy work on HIV being led by researchers at Temple Uni- versity’s Lewis Katz School of Medicine, and Philadelphia’s reputation as “Cellicon Valley” comes to life. The team of Tem-

Lancaster York Reading Hanover Malvern Hunt Valley

Call Steve Today 781-740-2900 skelley@marejournal.com


- DC

Geotechnical Design & AnalyƐŝƐͻnvironmental Site Assessments and

www.earthengineering.com Corporate Headquarters: 610-277-0880 ͻ Lehigh Valley: 610-967-4540 Central PA: 717-697-5701 ͻ South Jersey: 856-768-1001

Made with FlippingBook flipbook maker